Publications

Scholarly Journals--Published

• Ling T C, Slater J M, Nookala P, Mifflin R, Grove R, . . . Yang G Y. (2014). Protons Offer Reduced Cardiopulmonary Exposure for Patients Receiving Radiation Therapy for Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 90, S339-S340. (09/2014)
• Ling T C, Slater J M, Mifflin R, Nookala P, Grove R, . . . Yang G. (2014). Evaluation of Normal Tissue Exposure in Patients Receiving Radiation Therapy for Pancreatic Cancer Based on RTOG 0848. International Journal of Radiation Oncology Biology Physics, 90, S358-S359. (09/2014)
• Ling Ted Chen-Tai, Slater Jerry Monroe, Mifflin Rachel, Nookala Prashanth, Grove Roger, . . . Yang Gary. (2014). A comparison of proton and photon radiotherapy in reducing cardiac exposure for patients receiving radiation therapy for distal and esophagogastric junction cancer. Journal of Clinical Oncology, 32(3), . (01/2014)
• Slater Jerry Monroe, Ling Ted Chen-Tai, Nookala Prashanth, Mifflin Rachel, Grove Roger, . . . Yang Gary. (2014). A treatment planning evaluation of protons versus IMRT in pancreatic cancer: A comparative study. Journal of Clinical Oncology, 32(3), . (01/2014)
• Ling Ted C, Slater Jerry M, Nookala Prashanth, Mifflin Rachel, Grove Roger, . . . Yang Gary Y. (2014). Analysis of Intensity-Modulated Radiation Therapy (IMRT), Proton and 3D Conformal Radiotherapy (3D-CRT) for Reducing Perioperative Cardiopulmonary Complications in Esophageal Cancer Patients. Cancers, 6(4), 2356-2368. Background. While neoadjuvant concurrent chemoradiotherapy has improved outcomes for esophageal cancer patients, surgical complication rates remain high. The most frequent perioperative complications after trimodality therapy were cardiopulmonary in nature. The radiation modality utilized can be a strong mitigating factor of perioperative complications given the location of the esophagus and its proximity to the heart and lungs. The purpose of this study is to make a dosimetric comparison of Intensity-Modulated Radiation Therapy (IMRT), proton and 3D conformal radiotherapy (3D-CRT) with regard to reducing perioperative cardiopulmonary complications in esophageal cancer patients. Materials. Ten patients with esophageal cancer treated between 2010 and 2013 were evaluated in this study. All patients were simulated with contrast-enhanced CT imaging. Separate treatment plans using proton radiotherapy, IMRT, and 3D-CRT modalities were created for each patient. Dose-volume histograms were calculated and analyzed to compare plans between the three modalities. The organs at risk (OAR) being evaluated in this study are the heart, lungs, and spinal cord. To determine statistical significance, ANOVA and two-tailed paired t-tests were performed for all data parameters. Results. The proton plans showed decreased dose to various volumes of the heart and lungs in comparison to both the IMRT and 3D-CRT plans. There was no difference between the IMRT and 3D-CRT plans in dose delivered to the lung or heart. This finding was seen consistently across the parameters analyzed in this study. Conclusions. In patients receiving radiation therapy for esophageal cancer, proton plans are technically feasible while achieving adequate coverage with lower doses delivered to the lungs and cardiac structures. This may result in decreased cardiopulmonary toxicity and less morbidity to esophageal cancer patients. [ABSTRACT FROM AUTHOR] Copyright of Cancers is the property of MDPI Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) (2014) (link)
• Slater Jason M, Ling Ted C, Slater Jerry D, & Yang Gary Y. (2014). Palliative radiation therapy for primary gastric melanoma. J Gastrointest Oncol, 5(1), E22-6. INTRODUCTION: Primary gastric melanoma is an exceedingly rare cause of upper gastrointestinal bleeding (GI bleeding). Prior reports of primary gastric melanoma have mostly been treated with surgery with utilization of radiation therapy being unreported. Radiation therapy has been used to palliate bleeding of other cancers including lung, bladder, cervix, and more recently primary gastric cancers. CASE PRESENTATION: This case documents an 87-year-old male who presented with fatigue and melena, and was found to have severe anemia. Endoscopy with biopsy revealed an isolated focus of melanoma. After discharge, he presented two days later and was found to have continued bleeding. Because he was deemed a poor surgical candidate he elected to undergo palliative radiation therapy for bleeding control. DISCUSSION: The diagnosis of primary verses metastatic melanoma is a topic of debate. Case reports of patients with no known extra-gastric primary have undergone surgical treatment with varying outcomes. Patients with metastatic gastric melanoma have relied on chemotherapy and radiation in addition to surgery, with radiation being used in the palliative setting. The use of radiation to control bleeding in other cancers including primary gastric adenocarcinoma has been previously studied. This case documents the utilization of radiation therapy in bleeding due to primary gastric melanoma. CONCLUSIONS: Radiation therapy can provide adequate bleeding palliation in patients with primary gastric melanoma. (2014) (link)
• Yang G Y, Malik N K, Chandrasekhar R, Ma W W, Flaherty L, . . . May K S. (2013). Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol, 4(4), 361-9. PURPOSE: RTOG 9704 demonstrated a prognostic role for postoperative CA 19-9 in patients with resectable pancreatic carcinoma following surgery. Our study aimed to investigate whether CA 19-9 provided similar prognostic information in patients with locally advanced unresectable pancreatic cancer (LAPC) treated with chemoradiotherapy (CRT) and to determine whether such endpoints should therefore be reported in future randomized trials. METHODS AND MATERIALS: Between December 1998 and October 2009, 253 patients with LAPC were treated with 5-fluourouracil-based concurrent CRT at our institution. Median radiation dose was 50.4 Gy. Only patients with a bilirubin of less than 2 mg/dL at the time the CA 19-9 was evaluated were included in the analysis to avoid the confounding effect of hyperbilirubinemia. Of the eligible patients, 54 had pre and post CRT CA 19-9 values available. The median age was 68 years and 52% were female. Categorized versions of the first post-CRT CA 19-9 were tested in 50 point increments beginning at <50 to >1,000 and percent change in pre to post-CRT CA 19-9 using cut points of 10% increments from <0% (increased) to >90%. Survival was measured from the date of first post CRT CA 19-9 level until death or last follow-up. Univariate and multivariate statistical methodologies were used to determine significant prognostic factors for overall survival. RESULTS: Median CA 19-9 prior to CRT was 363 U/mL and post CRT median was 85.5 U/mL. Following CRT, patients with a decrease of >90% from their baseline CA 19-9 level had a significantly improved median survival than those that did not (16.2 vs. 7.5 months, P=0.01). The median survival of patients with a CA 19-9 level lower than the median post CRT value was 10.3 months, compared with 7.1 months for those with a CA 19-9 level greater than the median (P=0.03). Post CRT CA 19-9 less than 50 U/mL and histologic grade I-II also showed prognostic significance (both P=0.03). In multivariate analysis, post CRT CA 19-9 less than the median level of 85.5 U/mL was an independent prognostic factor for overall survival (HR 0.34; 95% CI, 0.13-0.85, P=0.02). CONCLUSIONS: Our results indicate that post treatment CA 19-9 is predictive for overall survival in patient with LAPC following CRT. We recommend that pre and post treatment CA 19-9 levels be obtained in patients receiving CRT and that these values be considered for prognostic nomograms and future clinical trials. (12/2013) (link)
• Iyer R, Chhatrala R, Shefter T, Yang G, Malhotra U, . . . Khushalani N. (2013). Erlotinib and Radiation Therapy for Elderly Patients with Esophageal Cancer - Clinical and Correlative Results from a Prospective Multicenter Phase 2 Trial. Oncology, 85(1), 53-58. Purpose: Elderly patients with esophageal cancer who are not candidates for chemoradiation may benefit from targeted agents; hence erlotinib combined with radiotherapy was evaluated in this trial. Materials and Methods: Patients >65 years with carcinoma of the thoracic esophagus or gastroesophageal junction who were not eligible for platinum-based treatment received erlotinib daily for 1 year starting on day 1 of radiotherapy [50.4 Gy days 1-28 (Mon-Fri) at 1.8 Gy per fraction]. Response was assessed by endoscopy and computed tomography. The primary endpoint was overall survival (OS), and secondary endpoints were complete response, progression-free survival (PFS) and toxicity. Results: The ECOG performance status in the 17 study patients was 0,1 and 2 in 2, 12 and 3 patients, respectively; 1, 5, 7 and 4 patients were in stage I, II, III and IV, respectively; adenocarcinoma was noted in 16 patients and squamous cell carcinoma in 1; there were 3 current, 12 past and 2 never smokers. Median OS was 7.3 months (95% confidence interval, CI: 3.8-22.3) with 14 deaths. There were 2 mucosal complete responses, 1 residual carcinoma in situ and 3 partial endoscopic responses in 9 patients who had endoscopy after radiotherapy. Estimated PFS was 4.5 months (95% CI: 2.4-7.3). Progression was distant (n = 3), locoregional (n = 6), unknown (n = 5) and too early (n = 3). Estimated 1-year survival was 29% (95% CI: 11-51%), 5 patients lived >12 months. Treatment-related toxicities of grade 3-4 occurred in 5 patients. Patients with epidermal growth factor receptor amplification and never smokers had the longest OS (22.3 and 16.6 months, respectively). Conclusions: Erlotinib with radiotherapy is tolerable and warrants further biomarker-driven evaluation in this population. Copyright (C) 2013 S. Karger AG, Basel. (2013) (link)
• Malik N K, May K S, Chandrasekhar R, Wee W, Flaherty L, . . . Yang G Y. (2012). Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol, 3(4), 326-34. PURPOSE: We retrospectively analyzed the results of patients with locally advanced unresectable pancreatic cancer (LAPC) treated with either chemoradiation (CRT) or chemotherapy alone over the past decade. METHODS AND MATERIALS: Between December 1998 and October 2009, 116 patients with LAPC were treated at our institution. Eighty-four patients received concurrent chemoradiation [RT (+) group], primarily 5-flourouracil based (70%). Thirty-two patients received chemotherapy alone [RT (-) group], the majority gemcitabine based (78%). Progression-free survival (PFS) and overall survival (OS) were calculated from date of diagnosis to date of first recurrence and to date of death or last follow-up, respectively. Univariate statistical analysis was used to determine significant prognostic factors for overall survival. RESULTS: Median patient age was 67 years. Sixty patients were female (52%). Median follow-up was 11 months (range, 1.6-59.4 months). The RT (+) group received a median radiation dose of 50.4 Gy, was more likely to present with ECOG 0-1 performance status, and experienced less grade 3-4 toxicity. PFS was 10.9 versus 9.1 months (P=0.748) and median survival was 12.5 versus 9.1 months (P=0.998) for the RT (+) and RT (-) groups respectively (P=0.748). On univariate analysis, patients who experienced grade 3-4 toxicity had worse overall survival than those who did not (P=0.02). CONCLUSIONS: Optimal management for LAPC continues to evolve. Patients who developed treatment-related grade 3-4 toxicity have a poorer prognosis. Survival rates were not statistically significant between chemotherapy and chemoradiotherapy groups. (12/2012) (link)
• Guo C Q, Yi H F, Yu X F, Zuo D M, Qian J, . . . Wang X Y. (2012). In Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer. Molecular Cancer Therapeutics, 11(11), 2331-2341. Given the complexity of prostate cancer progression and metastasis, multimodalities that target different aspects of tumor biology, for example, radiotherapy in conjunction with immunotherapy, may provide the best opportunities for promoting clinical benefits in patients with high-risk localized prostate cancer. Here, we show that intratumoral administration of unmodified dendritic cells (DC) failed to synergize with fractionated radiotherapy. However, ionizing radiation combined with in situ vaccination with DCs, in which the immunosuppressive scavenger receptor A (SRA/CD204) has been downregulated by lentivirus-mediated gene silencing, profoundly suppressed the growth of two mouse prostate cancers (e.g., RM1 and TRAMP-C2) and prolonged the lifespan of tumor-bearing animals. Treatment of subcutaneous tumors with this novel combinatorial radioimmunotherapeutic regimen resulted in a significant reduction in distant experimental metastases. SRA/CD204-silenced DCs were highly efficient in generating antigen or tumor-specific T cells with increased effector functions (e.g., cytokine production and tumoricidal activity). SRA/CD204 silencing-enhanced tumor cell death was associated with elevated IFN-gamma levels in tumor tissue and increased tumor-infiltrating CD8(+) cells. IFN-gamma neutralization or depletion of CD8(+) cells abrogated the SRA/CD204 downregulation-promoted antitumor efficacy, indicating a critical role of IFN-gamma-producing CD8(+) T cells. Therefore, blocking SRA/CD204 activity significantly enhances the therapeutic potency of local radiotherapy combined with in situ DC vaccination by promoting a robust systemic antitumor immunity. Further studies are warranted to test this novel combinatorial approach for translating into improved clinical outcomes in patients with prostate cancer. Mol Cancer Ther; 11(11); 2331-41. (C) 2012 AACR. (11/2012) (link)
• Desai V, Weil MH, Tang W, Yang G, Bisera J., Gastric intramural PaCO2 during peritonitis and shock. Chest. 1993;104:4:1254-1258. Yang GY, Matthews RH, Prophylactic cranial irradiation in small-cell lung cancer. The Oncologist. 2000;5:293-298. Landry JC, Yang GY, Neoadjuvant therapy for rectal cancer. Colorectal Cancer: Index & Reviews. 2000;1:3:4-7. Landry JC, Yang GY, Ting JY, Staley CA, Torres W, Esiashvili N,  Davis LW. Treatment of pancreatic cancer tumors with IMRT using the volume at risk approach:   Employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Medical Dosimetry. 2002;27:2:121-129 Yang GY, Wagner T, Thomas CR Jr, Multimodality therapy for rectal cancer. Current Problems in Cancer. 2004;28:6:312-342. Shaukat A, Mortazavi A, Demmy T, Nava H, Wilkinson N, Yang G, Kepner J, Javle M, Should preoperative endoscopy (EGD) be performed routinely for esophageal cancer patients after chemo-radiation treatment? Disease of the Esophagus. 2004;17:129-135. Palesty JA, Wang W, Javle MM, Yang GY, Gastric cancer after radiotherapy of pediatric hodgkin’s disease. Journal of Clinical Oncology. 2004;22:12: 2507-2509. Manjili MH, Wang XY, Macdonald IJ, Arnouk H, Yang GY, Pritchard MT, Subjeck JR, Cancer immunotherapy and heat shock proteins: Promises and challenges. Expert Opinion on Biological Therapy. 2004;4:3:363-373 Wang XY, Li Y, Yang GY, Subjeck JR, Current ideas about applications of heat shock proteins in vaccine design and immunotherapy. Int. J. Hyperthermia. 2005;21:717-722. Nallapareddy S, Wilding G, Yang GY, Iyer R, Javle M, Chemoradiation is a tolerable therapy for older adults with esophageal cancer. Anticancer Res. 2005;25:3055-3060. Yang GY, Wagner TD, Fuss M, Thomas CR, Multimodality approaches in pancreatic cancer. CA: A Cancer Journal for Clinicians. 2005;55:352-367. Tripp P, Malhotra H, Javle M, Shaukat A, Russo R, DeBoer S, Podgorsak M,    Nava H, Yang GY. Risk of cardiac complications following neoadjuvant chemoradiation for esophageal cancer. Disease of the Esophagus. 2005;18:400-405. Javle MM, Nwogu CE, Donohue KA, Iyer RV, Brady WE, Khemka SV, Smith JL, Demmy TL, Yang GY, Nava HR. Management of locoregional stage esophageal cancer: A single center experience. Disease of Esophagus. 2006;19(2):78-83 Li Y, Wang XY, Yang GY, Subjeck J, Repasky E, Generation of antitumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine. 2006;19;24:5360-70. Yang GY, Schoenwetter M, Wagner TD, Donohue K, Kuettel M,   Misrepresentation of publications among radiation oncology residency applicants. Journal of American College of Radiology. 2006;3:259-264.  Fakih MG, Rajput A, Yang GY, Pendyala L, Toth K, Smith JL, Lawrence DD, Rustum YM, A phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006;65;5:1462–1470. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. Chemotherapy-induced carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer. Oncology 2006;70:49–53. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR, Palliation of malignant dysphagia in esophageal cancer: A literature-based review. The Journal of  Supportive Oncology. 2006:4:8:365-373. Park EM, Ramnath N, Yang GY, Ahn JY, Park Y, Lee TY, Shin HS, Yu J, Ip C, Park YM, High superoxide dismutase and low glutathione peroxidase activities in red blood cell predict susceptibility of lung cancer patients to radiation pneumonitis. Free Radical Biology and Medicine. 2007:42:280-7. Yang GY, Li B, Wagner TD, Donohue K, Flaherty L, Kuettel M, Long term outcome of stage I seminoma. Am J. Clin Onc. 2007:30:205-210 O'Connor BM, Agrawal A, Lombardo JC, Nwogu CE, Iyer RV, Yang GY, Nava HR, Javle MM. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy for the treatment of locally advanced esophageal carcinoma: A single center experience. Cancer Journal. 2007:13(2):119-124. Yang GY, Thomas CR. Can sequencing of concurrent capecitabine and radiation therapy improve the therapeutic ratio in rectal cancer? Gastrointestinal Cancer Journal. 2007:1:64-65. Puthillath A. Dunn KB. Rajput A. Smith J. Yang G. Wilding GE. Tan W. Gupta B. Fakih MG. Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer. Clinical Colorectal Cancer. 2007:6(10):710-5 Javle MM, Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM. Epidermal growth factor (EGFR) directed therapy in esophageal cancer. Oncology. 73(5-6):281-9, 2007   Javle M, Yang GY, Review: Neoadjuvant chemoradiotherapy and chemotherapy improve survival in operable esophageal cancer, American College of Physcian Journal Club. 2007 Jul-Aug;147:19 Yang GY, Wagner TD, Thomas CR. The role of positron emission tomography in esophageal cancer,Gastrointestinal Cancer Research. 2008:2(1):3-10 Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding C, Black J, Nava H, Nwogu C, Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: Tissue effect predicts clinical response. Am J. Clin Onc. 2008:31(4):329-334 Patel MP, Puthilath A, Yang G, Fakih M. Neoadjuvant chemoradiation of rectal cancer: Is more better? Oncology. 2008:22(7):814-26; discussion 826, 828-31, 836 Wagner TD, Yang GY, Cetuximab: Its use in combination with radiation therapy and chemotherapy in the multimodality treatment of head and neck cancer, Recent Patents on Anti-Cancer Drug Discovery. 2008:3(2):76-83. Wagner TD, Wharton K, Donohue, K, Sperl M, Flaherty L, Jaggernauth W, Yap J, Fernando J, Landry J, Yang GY. Pure tubular breast carcinoma: A 34 year study of outcomes. The Breast Journal. 2008:14(5):512-513. Fakih M, BullardDunn K, Yang G, Pendyala L, Rustum Y, Andrews C, Ross ME, LeVea C, Puthillath A, Park YM, Rajput A. A phase II study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy with biological correlates in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2008:72(3):650-657 Hazard L, Yang G, McAleer MF, Hayman J, Willett C, Principles and techniques of radiation therapy for esophageal and gastroesophageal junction cancers, Journal of NCCN, 2008:6(9):870-878 Ajani JA. Barthel JS. Bekaii-Saab T. Bentrem DJ. D'Amico TA. Fuchs CS. Gerdes H. Hayman JA. Hazard L. Ilson DH. Kleinberg LR. McAleer MF. Meropol NJ. Mulcahy MF. Orringer MB. Osarogiagbon RU. Posey JA. Sasson AR. Scott WJ. Shibata S. Strong VE. Swisher SG. Washington MK. Willett C. Wood DE. Wright CD. Yang G. NCCN Esophageal Cancer Panel. Esophageal cancer. Journal of the National Comprehensive Cancer Network, 2008:6(9):818-49 Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G; NCCN Gastric Cancer Panel. J Natl Compr Canc Netw. 2010 Apr;8(4):378-409 Javle MM, Yang G, Nwogu CE, Wilding GE, O’Malley L, Vinjamaram S, Schiff MD, LeVea C, Clark KR, Prey JD, Smith PF, Nava HR,Pendyala L, Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis, Cancer Investigation 2009:27(2):193-200  McCloskey S, Yang GY, Principles and techniques of radiation therapy for gastric cancers, Gastrointestinal Cancer Research 2009:3:17-22  Yang GY, McCloskey SA, Khushalani NI, Principles and techniques of radiation therapy for esophageal and gastroesophageal junction cancers, Gastrointestinal Cancer Research 2009:3(1):S6-S10 Yang GY, Ott K, Accomplishments in 2008 in the management of esophageal Cancer, Gastrointestinal Cancer Research 2009:3(4):S26-S30 Hopkins S, Yang GY, Positron emission tomography's utility in esophageal cancer management, J Thoracic Dis 2009; 1: 29-33. Hopkins S, Yang GY, Positron emission tomography's changing significance in the treatment of esophageal cancer, World J. of Gastrointestinal Oncology 200 (1):34-37  Chadha MK, Litwin A, Levea C, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. Journal of Pancreas 2009:10(5):10001-10004. Yang GY, Helical tomotherapy for radiochemotherapy in esophageal cancer: A preferred plan? Journal of Thoracic Disease 2009:1(1):3-4 Wagner TD, Khushalani NI, Yang GY, Clinical T2N0M0 carcinoma of thoracic esophagus, Journal of Thoracic Disease 2010:2:36-42 Wagner TD, Yang GY, The role of Pemetrexed in concurrent chemoradiotherapy for non-small cell lung cancer, Current Drug Target. 2010:11(1): 67-73   Abbas A, Yang G, Fakih M. Management of anal cancer in 2010 Part 1: Overview, screening, and diagnosis. Oncology. 2010:24(4):364-9 Abbas A, Yang G, Fakih M. Management of anal cancer in 2010 Part 2: Current Treatment Standards and Future Directions. Oncology. 2010:24(5):417-24 Zheng J, Wang G, Yang GY, Wang D, Luo X, Chen C, Zhang Z, Li Q, Xu W, Li Z, Wang D, Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma, Japanese Journal of Clinical Oncology 2010;40(5):425-31 Salerno May K, Khushalani NI, Chandrasekhar R, Wilding GE, Iyer RV, Ma WW, Flaherty L, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle MM, Yang GY, Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies following chemoradiation to the abdomen, Int J Radiat Oncol Biol Phys. 2010:76(4):1193-1198 Yang GY, Salerno May K, Iyer RV, Chandrasekhar R, Wilding GE, McCloskey SA, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M, Thomas CR Jr, Renal atrophy secondary to chemoradiation treatment for abdominal malignancies, Int J Radiat Oncol Biol Phys. 2010;78(2):539-546 Salerno May K, Yang GY, Khushalani NI, Chandrasekhar R, Wilding GE, Flaherty L, Russo RC, Warner JC, Yap JC, Iyer RV, Nwogu CE, Yendamuri SS, Nava HR, Lamonica D, Thomas CR Jr, Association of technetium99m MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies, J Gastroint Oncol. 2010;1:7-15 Yap J, Malhotra H, Yang GY, Intensity Modulated Radiation Therapy in the Treatment of Esophageal Cancer, Thoracic Cancer 2010;1:62-69. Yang GY, Message from the Editor-in-Chief, Journal of Gastroint Oncol 2010;1:1 Lee RY, Flaherty L, Khushalani NI, Kanehira K, Nwogu C, Yendamuri S, Nava HR, Yang GY, Aorto-esophageal fistula: a rare fatal case caused by esophageal malignancy,  Journal of Gastroint Oncol 2010;1:64-67 Wagner TD, Fakih M, Yang GY, Management of stage II/III rectal cancer, J Gastrointest Oncol 2010; 1: 112-119 Hopkins S, Fakih M, Yang GY, PET as predictor of rectal cancer response during or following neoadjuvant chemoradiation,  World J  Gastrointest Oncology 2011;2:213-                217 Hopkins S, Yang GY, FDG PET imaging in the staging and management of gastric cancer,  Journal of Gastroint Oncol 2011;2:39-42 Salerno May K, Yang GY, Khushalani NI, The role of radiation in the peri-operative treatment of gastroesophageal cancer, Current Treatment Options in Oncology 2011;12:61–71 Yendamuri S, Gutierrez L, Oni A, Mashtare T, Khushalani N, Yang G, Nava H, Demmy T, Nwogu C, Does circular stapled esophagogastric anastomotic size affect the incidence of post-operative strictures? Journal of Surgical Research 2011;165:1-4 Kang J, Slater JD, Yang GY, Proton therapy for esophageal cancer, Thoracic Cancer 2012;3:91-93 Malik NK, Salerno May K, Groman A, Patil1 S, Gibbs J, Kuvshinoff B, Ma W, Iyer R, Warren G, Yang GY, Treatment of locally advanced unresectable pancreatic cancer: A 10-year experience, Journal of Gastroint Oncol, 2012; 3(4):326-334. Ling TC, Kang JI, Slater JD, Yang GY, Proton therapy for gastrointestinal cancer, Translational Cancer Research, 2012;1(3):150-158 Ling TC, Kang JI, Bush DA, Slater JD, Yang GY, Proton therapy for hepatocellular carcinoma, Chinese Journal of Cancer Research, 2012, 24(4), 361-367 Guo CQ, Yi H, Yu X, Zuo D, Qian J, Yang G, Foster BA, Subjeck JR, Sun X, Mikkelson RB, Fisher PB, Wang XY. In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. Molecular Cancer Therapeutics 2012;11(11): 2331-2341 Kang JI, Ling TC, Slater JD, Yang GY, Stereotactic Body Proton Therapy for Liver Metastases, Translational Cancer Research, 2012;1(3):150-158 Yang GY, Malik N, Chandrasekhar R, , Ma WW Watroba N, Flaherty L, Iyer R, Kuvshinoff BW, Gibbs JF, Wilding GE, Salerno May K, Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer, Journal of Gastroint Oncol, 2013;4(4):361-369 Renuka I, Chhatrala R, Shefter T, Yang G, Malhotra U, Wei T, LeVea C, Robins M,Khushalani N, Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial, Oncology, 2013;85(1):53-8 Ling TC, Slater JA, Kazanjian KK, Howard FD, Senthil M, Garberoglio CA, Slater JD, Yang GY, Surgical and radiation therapy management of recurrent anal melanoma, Journal of Gastroint Oncol,2014;5(1):E7-E12 Slater JA, Ling TC, Slater JD, Yang GY, Radiation therapy for primary gastric melanoma, Journal of Gastroint Oncol, 2014;5(1):E22-E26 Ling TC, Slater JM, Nookala P, Mifflin R, Grove R, Ly AM, Patyal B, Slater JD, Yang GY,  Analysis of Intensity-Modulated Radiation Therapy (IMRT), proton and 3D Conformal Radiotherapy (3D-CRT) for reducing perioperative cardiopulmonary complications in esophageal cancer patients, Cancers 2014, 6(4), 2356-2368  Slater JM, Ling TC, Nookala P, Mifflin R, Grove R, Ly AM, Patyal B, Slater JD, Yang GY, Protons Offer Reduced Tissue Exposure for Patients Receiving Radiation Therapy for Pancreatic Cancer, Int J Particle Ther, 2014;1(3):702-710 Ling TC, Slater JM, Mifflin R, Nookala P, Grove R, Ly AM, Patyal B, Slater JD, Yang GY, Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848, Journal of Gastroint Oncol, 2015;6(2):108-14 (Present)

Abstract

• Ling T C, Barnes S, Yang G, Yeo I, Grove R, Slater J, & Bush D. (2013). A Dosimetric Comparison of Hepatocellular Carcinoma Treated by Protons and IMRT. International Journal of Radiation Oncology Biology Physics, 87(2), S740-S740. (10/2013)
• Malik N K, Patil S, Groman A, Nava H, Yendamuri S, . . . May K. (2011). Outcomes in Patients 65 Years or Older Treated with Trimodality Therapy for Esophageal Carcinoma. International Journal of Radiation Oncology Biology Physics, 81(2), S312-S312. (2011)
• Patil S S, May K S, Hackett R A, Hales L D, VanBenthuysen L T, . . . Warren G W. (2011). A Comparison of VMAT, IMRT, and 3DCRT in the Treatment Planning of Patients with Distal Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 81(2), S324-S325. (2011)
• Malik N K, May K S, Groman A, Patil S, Gibbs J, . . . Yang G. (2011). Outcomes and Tolerability of Treatment for Locally Advanced Pancreatic Cancer Patients 65 Years or Older. International Journal of Radiation Oncology Biology Physics, 81(2), S336-S336. (2011)
• Malik N K, Patil S, Groman A, Nava H, Yendamuri S, . . . May K. (2011). Outcomes in Patients 65 Years or Older Treated with Trimodality Therapy for Esophageal Carcinoma. International Journal of Radiation Oncology Biology Physics, 81(2), S312-S312. (2011)
• (PEER REVIEWED)   Desai V, Weil  MH, Tang W, Yang G., Renal cortical hypercarbia during experimental septic shock. Clinical Research 1991;39:3:706A. Gazmuri RJ, Weil MH, Sun S, Tang W, Yang G., Amplitude of ventricular fibrillation waveforms and resuscitability. Chest 1992;102:2:127S.  Desai V, Weil MH, Tang W, Sun S, Yang G, Tissue hypercarbia during experimental septic shock. Chest 1992;102:2:157S. Ting JY, Ghavidel S, Yang GY, Davis LW, Feasibility of using a 0.5-cm MLC for radiosurgery purpose. World Congress on Medical Physics and Biomedical Engineering Chicago, IL, 2000. Landry JC, Harris W, Yang GY, Staley C, Bhalla K, Neoadjuvant treatment with gemcitabine, cisplatin, 5-FU and accelerated hyperfractionated radiation therapy in advanced gastrointestinal malignancies: Results of a phase I study. RSNA, Chicago, IL, 2000. Ting JY, Yang GY, Butker E, Helton D, Davis LW, Clinical implantation of electronic tissue compensation using dynamic multileaf collimators (DMLC). 47th Annual Meeting of the Radiation Research Society, Albuquerque, NM, 2000. Yang GY, Landry JC, Ting JY, Pablo JA, Davis LW, A "Target specific approach" in treatment portal designs. 47th Annual Meeting of the Radiation Research Society, Albuquerque, NM, 2000. Yang GY, Ting JY, Landry JC, Davis LW, Manpower and equipment requirement for IMRT with inverse treatment planning. World Congress on Medical Physics and Biomedical Engineering, Chicago, IL, 2000. Yang GY, Landry JC, Ting JY, Davis LW.  IMRT reduces the dose to the small bowel for patients with pancreatic cancer.  49th Annual Meeting of the Radiation Research Society, Reno, NV, 2002. Yang GY, Landry JC, Ting JY et al.  Comparison of DVH and normal tissue complication probability (NTCP) for small bowel in patients with pancreatic cancer receiving IMRT with three-dimensional conformal therapy (3D-CRT).  Proceedings of ASCO, 2002. Shaukat A, Mortazavi A, Demmy T, Yang GY, Hector N, Kepner J, Javle M,  Should preoperative endoscopy (EGD) be performed routinely for esophageal cancer patients after chemo-radiation treatment?  Proceedings of ASCO, 2003. Othman E, Ummadi S, Bundy B, Yang GY, Walsh D, Nava H, Gibbs J, Oleksowicz L, Javle M.  Chemoradiation for elderly patients with esophageal cancer.  Proceedings of ASCO, 2003. Donthireddy K, Wilkinson N, Lawrence D, Fakih M, Rajput A, Walsh D, Yang GY, Javle M.  Neoadjuvant chemoradiotherapy for rectal cancer:  Clinical experience and prognosis.  Proceedings of ASCO, 2003. Tripp P, Malhotra HK, Gergel T, Russo R, de Boer S, Podgorsak M, Jaggernauth W, Yang GY.  Change in cardiac function following neoadjuvant chemoradiation for esophageal cancer.  Proceedings of American Association of Clinical Research (AACR), 2004. Javle M, Khemka S, Donohue K, Demmy T, Yang GY, Smith J., Nava H, Douglass H.  The role of surgery in the management of loco-regional esophageal cancer.  Society of Surgical Oncology, 2004. Yang GY, Schoenwetter M.  Assessment and improvement of systems-based practice competency through 360-degree feedback:  A radiation oncology residency program experience.  Accreditation Council for Graduate Medical Education(ACGME)/American Board of Medical Specialties (ABMS) Joint Conference on System-Based Practice, 2004. Ailawadhi S, Rajput A, Yang GY, Smith J, Sunga A, Fakih M.  Carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer receiving systemic chemotherapy. ASTRO/ASCO Gastrointestinal Cancers Symposium, 2005. Yang GY, Schoenwetter M, Harvey V.  Assessment and improvement of professionalism through 360-degree feedback.  Accreditation Council for Graduate Medical Education (ACGME) Annual Education Conference, 2005. Fakih M, Rajput A, Smith J, Flaherty L, Yang GY  A phase I study of weekly oxaliplatin and daily capecitabine and radiation therapy in locally advanced rectal cancer. Proceedings of ASCO, 2005. Yang GY, Wharton K, Wagner TD, Donohue K, Tripp P, Khagany K., Thompson G, Martin J, Hare G, Jaggernauth W.  Pure Tubular Breast Carcinoma: A Study of Outcomes from 1971-2004. Proceedings of ASCO, 2005. O'Connor BM, Agrawal A, Lombardo JC, Nwogu CE, Iyer RV, Yang GY, Nava HR, Javle MM. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy for the treatment of locally advanced esophageal carcinoma: A single center experience. ASCO Gastrointestinal Cancers Symposium, 2006. Javle M, Iyer R, O'Malley L, Yang G, Lawrence D, Nwogu CE, Nava H. Phase I study of capecitabine, oxaliplatin, and radiotherapy for locally advanced esophageal cancer. ASTRO/ASCO Gastrointestinal Cancers Symposium, 2006. Reddy NM, Yu Y, Yang G, Rajput A, Smith J, Fakih MG. Outcomes and toxicities among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation: A single institution study. ASTRO/ASCO Gastrointestinal Cancers Symposium, 2006 Javle M, Smith P, Iyer R, O'Malley L, Yang GY, Nwogu CE, Nava H, Flaherty L, Pendyala L. Phase I pharmacokinetic, pharmacodynamic study of neoadjuvant capecitabine, oxaliplatin and radiotherapy for locally advanced esophageal cancer” American Association for Cancer Research (AACR), 2006. Yu J, ReddyNM, Rajput A, Smith J, Yang G, Fakih M. Outcomes and toxicities among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent with chemoradiation - a single institution study. Proceedings of ASCO, 2006. Wagner TD, Yang GY, Park Y, Hare G, Ramnath N. A Phase II study using concurrent intensity modulated radiation therapy (IMRT) and carboplatin with docetaxel for patients with unresectable stage III non-small cell lung cancer. Radiation Research Society Annual Meeting, 2006. Yang GY, Park EM, Ramnath N, Ahn JY, Park Y, Lee TY, Shin HS, Yu J, Ip C, Park YM, High superoxide dismutase and low glutathione peroxidase activities in red blood cell predict susceptibility of lung cancer patients to radiation pneumonitis. ASTRO, 2006. Yang GY, Kanter P, Chen X, Subjeck JR, Repasky EA, Wagner TD, Manjili MH. Preclinical safety evaluation of HSP110-HER2/neu vaccine. ASTRO, 2006. O’Connor B, Gomez J, Pak Y, Yang G, Kuettel M, Jaggernauth W. Limited-Field radiation is effective in preventing heterotopic ossification. ASTRO 2006. Gupta B, Abdel-Raheem S, Tan W, Wilding G, Smith J, Yang G, Rajput A, Bullard Dunn K, Fakih MG. Complications and efficacy in patients with unresected primary colorectal cancer treated with combination chemotherapy. GI ASCO 2007. Pande AU, Iyer R, Nava H, Yang G, Nwogu C, Schiff M, Levea C, Black J, Javle M. Gefitinib (ZD1839) with oxaliplatin and radiotherapy for esophageal carcinoma. GI ASCO 2007 Javle M, Punnam V, Mashtare T, Yang G, Iyer R, Nwogu C, Nava H, Wilding G. Preoperative vs. postoperative therapy for locally advanced esophageal cancer: Review of Surveillance, Epidemiology and End Results (SEER) database. GI ASCO 2007. Chadha MK, Lin P, Javle M, Iyer R, Driscoll D, Nava H, Yang G, Levea C, Cytokeratin staining to predict residual disease in patients undergoing neoadjuvant chemoradiation for esophageal cancer. GI ASCO 2007. Durrani FA, Cao S, Park YM, Thompson G, Martin JM, Yang GY, Kuettel MR, Rustum YM, Synergistic effect of selenium compounds with radiation therapy in human A549 lung xenografts. AACR 2007 Yap JC, Yang G, Impact of surgical treatment on survival in patients with primary rectal melanoma. ASCO 2007. Fakih MG, Rajput A, BullardDunn K, Yang GY, Pendyala L, Toth K, Andrews C, Rustum Y, Ross M, Park Y, A phase II neoadjuvant study of capecitabine plus oxaliplatin and radiation therapy in stage II-III rectal cancer: efficacy results and identification of Prx-1 as a new marker of response. GI ASCO 2008. Yang GY, Flaherty L, Wagner TD, Yap JC, Chandrasekhar R, Wilding G, Khushalani NI, Iyer RV, Lamonica D, Thomas CR Jr.Subclinical impairment of renal function following abdominal radiotherapy: An analysis using specific scintigraphic and biochemical endpoints. ASTRO 2008 Yang GY, ParikhKS, Flaherty L, Chandrasekhar R, Wilding G, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle M. Renal function after radiotherapy to the abdomen. ASTRO 2008 Jaggernauth W, Tchabo N, Yang G, Rodabaugh K, Lele S, Singh A, McCloskey S. High distant failure rate despite good local control in high risk early stage endometrial cancer. ASTRO 2008 McCloskey SA, Yang GY, Flaherty L, Chandrasekhar R, Wilding G, Salerno May K, Hackett RA, Thompson GM, Gomez JA, Thomas CR Jr. Renal atrophy secondary to radiation treatment of abdominal malignancies. Annual Meeting of the Radiation Research Society, 2008. McCloskey SA, Tchabo NE, Mashtare T, Andrews C, Singh AK, Yang GY, Rodabaugh K, Odunsi K, Lele S, Jaggernauth W, High risk features predictive of distant failure in early stage endometrial cancer, Proceedings of the 90th Annual Meeting of the American Radium Society, 2008 Dad LK, Flaherty L, Hales LD, Fakih M, Bullard Dunn KM, Rajput A, Smith JL, Martin JM, Jaggernauth W, Yang GY, Concurrent chemotherapy and intensity-modulated radiation therapy (IMRT) for anal cancer: Acute morbidity and dosimetric profile, Annual Meeting of Radiological Society of North America (RSNA), 2008 Yang, GY, McCloskey SA, Khushalani NI, Yap JC, Nwogu C, Yendamuri SS, Nava HF, Thomas CR Jr, Principles of modern radiation techniques for esophageal and gastroesophageal cancers, Gastrointestinal Cancer Research. 2008:2(5): Suppl 3, S2 Khushalani N, Yang G, Nava H, Nwogu C, Demmy T, Nava M, Tan W, Pendyala L, Iyer R, Javle M, A phase II trial of oxaliplatin, capecitabine and radiation in resectable esophagus cancer, ASCO/ASTRO/SSO GI Cancer Symposium, 2009 Fora A, Yang G, BullardDunn K, Rajput A, Smith J, Fakih M, Chemoradiation in elderly patients with rectal cancer, ASCO/ASTRO/SSO GI Cancer Symposium, 2009 Patel A, Puthillath A, Yang G, Rajput A, BullardDunn K, Smith J, Fakih M, Pathological response and toxicities with capecitabine oxaliplatin plus radiation vs. fluoropyrimidine plus radiation in the neoadjuvant treatment of rectal cancer, ASCO/ASTRO/SSO GI Cancer Symposium, 2009 Bharthuar A, Kim F, Yang G, Kuvshinoff B, Iyer R, Cost-benefit analysis of treatment modality for stage III pancreatic carcinoma - A single institution experience, ASCO/ASTRO/SSO GI Cancer Symposium, 2009 Sahai RK, Bullard Dunn K, Fakih MG, Yang GY, Rajput A, Surgical outcome following neoadjuvant therapy for rectal cancer. ASCO/ASTRO/SSO GI Cancer Symposium, 2009 Salerno May K, Flaherty L, McCloskey SA, Chandrasekhar R, Wilding G, Russo RC, Khushalani NI, Iyer RV, Gibbs JF, Yang GY, Renal atrophy following chemoradiotherapy for abdominal malignancies. ASCO/ASTRO/SSO GI Cancer Symposium, 2009 May KS, Flaherty L, Russo RC, Chandrasekhar R, Wilding GE, Yang GY, Anlysis of clinical and dosimetric factors associated with change in renal function in patients with GI malignancies following chemoradiation to the abdomen. American Radium Society 91st Annual Meeting, 2009. Salerno May K, Yang GY, Iyer R, Chandrasekhar R, Wilding G, Khushalani NI, Gibbs JF, Fakih M, Renal atrophy secondary to chemoradiation treatment for abdominal malignancies. ASCO Annual Meeting 2009 Bharthuar A, Khoury T, Haas KN, Mashtare T, Black J, Baer M, Yang G, Khushalani N, Iyer RV, Expression of breast cancer resistance protein in esophageal cancers, ASCO Annual Meeting 2009 Yap JC, Yang GY, Fakih M, Mashtare T, Bullard Dunn K, Rajput A, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF, Primary adenocarcinoma of the anus: A 22-year population-based SEER database analysis, ASCO Annual Meeting 2009 (abstratc # 32334) Sharma R, Yang GY, Nava HR, Demmy TL, Nwogu CE, Yendamuri SS, Lamonica D, Tan W, Iyer RV, Khushalani NI, A single institution experience with neoadjuvant chemoradiation with irinotecan and cisplatin in locally advanced esophageal carcinoma, ASCO Annual Meeting 2009 Khushalani N, Miecznikowski J, Wang D, Nowak N, Nava H, Nava M, Tan W,  Iyer R, Yang G, Pendyala L, Capecitabine, oxaliplatin and radiation in resectable esophagus cancer: a phase II trial with gene expression profiling, ASCO Annual Meeting 2009 McCloskey SA, Yang GY, Hales LD, Andrews C, Mashtare TL, Khushalani NI, Nwogu C, Yendamuri SS, Kuvshinoff BW, Nava HF, Potential for reduced toxicity in the treatment of gastric gancer: A dosimetric comparison of 3-D conformal AP/PA-field and 4-field techniques, Sixth Annual Conference on Advances in the Multidisciplinary Treatment of Gastrointestinal Neoplasms, 2009 Gutierrez1 LA, Yendamuri SS, Demmy TL, Nava HR, Mashtare T, Khushalani NI, Yang GY Nwogu CE, Does Circular stapled esophagastric anastomotic size or leak affect the incidence of post operative strictures? 4th Annual Academic Surgical Congress, 2009 Salerno May K, Fakih MG, Khushalani NI, Chandrasekhar R, Wilding GE, Park L, Flaherty L, Russo R, Iyer R, Yang GY, Renal function following abdominal chemoradiotherapy for gastrointestinal malignancies in elderly patients, ASTRO Annual Meeting, 2009 Yang GY, Khushalani NI, Chandrasekhar R, Wilding GE, McCloskey SA, Flaherty L, Yap JC, Gibbs JF, Fakih MG, Salerno May K, Renal atrophy secondary to abdominal chemoradiotherapy: Receiver operating characteristic (ROC) analysis, ASTRO Annual Meeting, 2009 Lamonica D, Sharma R, TanW, Hopkins S, Yang G, Grossman Z, yer R, Nava H,  Khushalan N, Neoadjuvant chemoradiotherapy with cisplatin & irinotecan for esophageal carcinoma: Predictive value of FDG-PET.  World Molecular Imaging Congress, 2009 Salerno May K, Chandrasekhar R, Malhotra HK, Russo RC, Flaherty L, Wilding GE, Khushalani NI, Yang GY, Change in renal function as measured by technetium99m MAG-3 scintigraphy and biochemical endpoints following abdominal chemoradiation for gastrointestinal malignancies. 6th Annual International Society of Gastrointestinal Oncology Conference, 2009 Salerno May K, Chandrasekhar R, Flaherty L, Russo RC, Ma WE, Kuvshinoff B, Gibbs JF, Wilding GE, Yang GY, Change in renal function secondary to chemoradiotherapy for pancreatic cancer. GI Cancer Symposium, 2010 Khushalani NI, Yang G, Tan W, Miecznikowski J, Wang D, Iyer RV, Yendamuri SS, Nwogu CE, Nava HR, Javle MM, Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP) and radiation (RT) for esophageal cancer (EC). ASCO Annual Meeting 2010 Saadah K, Miller A, Prasad D, Yang G, Bellavia T, Iyer R, Khushalani N, Brain Metastases in Esophageal Carcinoma, ASCO Annual Meeting 2010 Iyer R, Yang G, Shefter T, Tan W, Nava H, Litwin A, LeVea C, Robins M, Khushalani N, Phase II multicenter study of erlotinib in combination with radiation therapy for elderly patients with esophageal carcinoma. ESMO Annual Meeting 2010 Yang GY, Malik N, Chandrasekhar R, Salerno May K, Watroba N, Flaherty L, Ma WW, Kuvshinoff BW, Wilding GE, Gibbs JF, Change in CA 19-9 Levels after Chemoradiotherapy Predicts Survival in Patients with Locally Advanced Unresectable Pancreatic Cancer.  ASTRO Annual Meeting, 2010 Malik N, Chandrasekhar R, Salerno May K, Ma WW, Flaherty L, Iyer RV, Kuvshinoff BW, Gibbs JF, Wilding GE, Yang GY, Chemoradiotherapy versus Chemotherapy Alone in Patients with Locally Advanced Unresectable Pancreatic Carcinoma: a 10-year Experience. ASTRO Annual Meeting, 2010 Salerno May K, Lillard S, Yang G, Fakih M, Bullard Dunn K, Does delaying surgical resection of locally advanced rectal cancer after neoadjuvant chemoradiation adversely affect outcomes? European Colorectal Congress 2010 Patil S, Malik N, May K , Hackett R, Hales L, Groman A, Yang G, Warren GW, A Comparison of IMRT and 3D CRT in the Treatment Planning of Patients with Distal Esophageal Cancer, GI Cancer Symposium, 2011 Iyer RV, Yang G, Schefter TE, Tan W, Nava HR, Levea C, Litwin A, Robins M, Khushalani NI, Phase II multicenter study of erlotinib with radiation therapy for elderly patients with esophageal carcinoma: Final report, GI Cancer Symposium, 2011 Malik N, Warren G, Khushalani N,  Yendamuri S, Patil S, Zeeck K, Papsidero T, Nava H, Yang G, May K, Outcomes of esophageal carcinoma patients treated with trimodality therapy: a single institution experience, American Radium Society's 93rd Annual Meeting, 2011 Malik NK, Warren GW, Yang G, Zeeck K, Papsidero T, Patil S, Khushalani NI, Sher T, Yendamuri SS, Nava HR, Salerno May K, Response-based outcomes in patients with esophageal cancer treated with primarily non-cisplatin and 5-fluorouracil–based trimodality therapy, ASCO 2011 Salerno May K,  Malik NK, Yang G, Patil S, Flaherty L, Khushalani NI, Sher T, Yendamuri SS, Nava HR, Warren GW, The effect of smoking history on response and survival outcomes patients with in esophageal cancer treated with neoadjuvant concurrent chemoradiotherapy followed by surgery, ASCO 2011 Patil SS, May KS, Hackett RA, Hales LD, VanBenthuysen LD, Malik NK, Schmitt JD, Yang GY, Warren GW, A comparison of VMAT, IMRT, and 3DCRT in the treatment planning of patients with distal esophageal cancer, ASTRO 2011 Malik NK, Salerno May K, Groman A, Patil1 S, Gibbs J, Kuvshinoff B, Ma W, Iyer R, Warren G, Yang G, Outcomes and tolerability of treatment for locally advanced pancreatic cancer patients 65 years or older, ASTRO 2011 Malik NK, Patil1 S, Groman A, Nava H, Yendamuri S, Nurkin S, Sher T, Warren G, Yang G, May K, Outcomes in patients 65 years or older treated with trimodality therapy for esophageal carcinoma, ASTRO 2011 Chhatrala R, Khushalani N, Yang G, Shefter T, Tan W, Iyer R,  Erlotinib and radiation therapy for elderly patients with esophageal cancer: Clinical and correlative results from a prospective multicenter phase II trial,  International Society of Gastrointestinal Oncology (ISGIO) Gastrointestinal Oncology Conference 2011 Kazanjian K, Cho M, Morgan J, Roos M, Senthil M, Yang G, Lum S, Wong J, Adoption of pelvic radiation therapy for stage II and III rectal cancer in California: A population based study from 1994-2008, Pacific Coast Surgical Association meeting 2012  Wang N, Patyal B, Kang J, Slater J, Yang G, Bush D, Proton liver radiotherapy: treatment planning comparison between deep inspiration breath-hold and respiratory gating techniques, Proton Therapy Cooperative Group (PTCOG) 2013 Yeo I, Nookala P, Gordon I, Schulte R, Patyal B, Yang G, Ling T, Bush D, Slater J,  Comparative proton and IMRT planning study for prostate cancer with biological tumor volume, Proton Therapy Cooperative Group (PTCOG) 2013 Ling T, Barnes S, Yang G, Yeo I, Grove R, Slater JD, Bush D, A dosimetric comparison of hepatocellular carcinoma treated by protons and photons, ASTRO 2013 Ling TC, Slater JM, Nookala P, Mifflin R, Grove R, Ly AM, Patyal B, Slater JD, Yang GY, Protons offer reduced normal-tissue exposure for patients receiving radiotherapy for pancreatic head cancer, ISGIO 2013 Ling TC, Slater JM, Mifflin R, Nookala P, Grove R, Ly AM, Patyal B, Slater JD, Yang GY, Protons offer reduced cardiac exposure for patients receiving radiotherapy for distal and esophagogastric junction cancer, GI Cancers Symposium 2014 Slater JM, Ling TC, Nookala P, Mifflin R, Grove R, Ly AM, Patyal B, Slater JD, Yang GY, A treatment planning evaluation of protons versus IMRT in pancreatic cancer: A comparative study, GI Cancers Symposium 2014 Ling TC, Slater JM, Mifflin R, Nookala P, Grove R, Ly AM, Patyal B, Slater JD, Yang GY, Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848, ASTRO 2014 Ling TC, Slater JM, Nookala P, Mifflin R, Grove R, Ly AM, Patyal B, Slater JD, Yang GY, Protons offer reduced cardiopulmonary exposure for patients receiving radiation therapy for esophageal cancer, ASTRO 2014 (Present)

Books and Chapters

•  Landry JC, Blackstock W, Yang GY, Choy H.  The Role of Gemcitabine in Combined Modality Therapy in Chemoradiation in Cancer Therapy, Humana Press Inc, 2003 (Chapter 6) Wagner TD, Javle M, Yang GY, Esophageal Tumors: Principles & Practice, Demos Medical Publishing, Inc, 2009 (Chapter 22) Giap H, Chuang EY, Yang GY, Particle Beam Therapy: Contemporary trends and reviews, AME Groups, 2014 (Editor) Yang GY, Landry J, Gastrointestinal Malignancies: New Innovative Diagnostics and Treatment, World Scientific Publishing Co, 2015 (Chapter 23) (Present)